| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Hemab Therapeutics Hldgs (NASDAQ:COAG) through any online brokerage.
Other companies in Hemab Therapeutics Hldgs’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Hemab Therapeutics Hldgs has a consensus price target of $54.71.
The stock price for Hemab Therapeutics Hldgs (NASDAQ: COAG) is $34.17 last updated October 20, 2026 at 5:00 PM EDT.
There are no upcoming dividends for Hemab Therapeutics Hldgs.
Hemab Therapeutics Hldgs does not have any upcoming earnings scheduled.
There is no upcoming split for Hemab Therapeutics Hldgs.
Hemab Therapeutics Hldgs is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
